Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

p140Cap enhances breast cancer chemosensitivity by limiting an ABCC1-enriched stem-like compartment via β-Catenin inhibition

Andrea Scavuzzo Matteo Poncina A. Lamolinara Alessandro Sarcinella Mahdis Jahanbin M. G. Filippone Laura Bottoni F. Tucci Yaron Vinik S. Lev Manuela Iezzi U. Ala D. Taverna F. Orso B. Belletti E. Turco S. Pece D. Tosoni Paola Defilippi Vincenzo Salemme
Aug 2026 · bioRxiv · 0 citations · 18 references
Biology

TL;DR

Clinically, analyses of breast cancer cohorts and patient-derived xenograft models identify p140Cap as predictive biomarker of chemotherapy response, proposing p140Cap-guided patient stratification, dose optimization and rational combination therapies.

DOI Semantic Scholar
View source

Similar papers

Open access Aug 2026

ST6GAL1 promotes cancer stem-like cell-associated paclitaxel resistance through the EGFR-mTOR-SOX2/BMI1 axis in non-small cell lung cancer

ST6GAL1-mediated α2,6-sialylation of EGFR contributes to the maintenance of CSLC-associated paclitaxel resistance through mTOR-SOX2/BMI1 signaling, which identifies ST6GAL1-dependent EGFR sialylation as a potential therapeutic target in CSLC-associated chemoresistance.

Yu-Xi Yang, Bing-Hui Liang, W. Hong et al. · 1 citation
Open access Aug 2026

Targeting breast cancer stem cells by restoring RBM38 function: mechanism and protein delivery therapy

Breast cancer stemness drives tumor progression and therapy resistance, yet the underlying mechanisms remain poorly understood. In this study, we observed that RBM38 expression gradually decreases during breast cancer progression in MMTV-PyMT transgenic mice. Using a model with targeted RBM38 expression in breast tissu...

Jun Yin, Ting Wang, Xuedan Han et al. · 0 citations
Aug 2026

Targeting the METTL14/Wnt9a/β-catenin pathway with pharmacological inhibitors enhances radiotherapy and immunotherapy efficacy in non-small cell lung cancer.

These findings establish METTL14 as a central pharmacological target whose inhibition suppresses the Wnt9a/β-catenin pathway, enhances radiotherapy and anti-PD-1 efficacy, and reduces CSC-driven progression in NSCLC.

Kai-Feng Ji, Rong Yu, Wei Zhang et al. · 0 citations
Open access Sep 2026

Honokiol Suppresses Stemness and Sensitizes Triple-Negative Breast Cancer to Chemotherapy via YAP/TAZ-TEAD Inhibition

Objectives: As an aggressive subtype of breast cancer, triple-negative breast cancer (TNBC) is constrained by the limited availability of effective treatments and the absence of well-validated therapeutic targets. This study aimed to explore whether honokiol, a potent YAP/TAZ inhibitor, suppresses stem cell–like proper...

Jiang-Nan Xia, Shan-Dong Zhu, Wei-Ling Qu et al. · 0 citations
Jul 2026

Abstract A088: SLC39A6-targeted combination therapy to reverse CAF-induced resistance in HER2+ breast cancer using a microfluidic platform

Findings identify SLC39A6 as a novel, actionable therapeutic target in CAF-rich HER2+ breast cancer and provide preclinical rationale for SLC39A6-directed ADC combination strategies, and establish a new paradigm for patient-specific drug screening in the context of the stromal tumor microenvironment.

Zeina S. Habli, Tiangyang Li, Mathew Poskus et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.